Brainsway Ltd. (NASDAQ:BWAY) is set to announce third quarter earning results on Wednesday 18th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BWAY to report 3Q20 revenue of $ 5.45 million.
For the full year, analysts anticipate top line of $ 21.11 million, while looking forward to loss of $ 0.27 per share bottom line.
Previous Quarter Performance
Brainsway Ltd. outlined loss for the second quarter of $ 0.03 per share, from the revenue of $ 4.82 million. The quarterly revenues decreased 15.44 percent compared with the same quarter last year. According to street consensus, BWAY was expected to report 2Q20 loss of $ 0.13 per share from revenue of $ 4.77 million. The bottom line results beat street analysts by $ 0.1 or 76.92 percent, at the same time, top line results outshined analysts by $ 0.05 million or 1.05 percent.
Stock Performance
Shares of Brainsway Ltd. traded up $ 0.14 or 2.29 percent on Tuesday, reaching $ 6.25 with volume of 5.90 thousand shares. Brainsway Ltd. has traded high as $ 6.30 and has cracked $ 6.14 on the downward trend
According to the previous trading day, closing price of $ 6.25, representing a 19.80 % increase from the 52 week low of $ 5.10 and a 51.24 % decrease over the 52 week high of $ 12.53.
The company has a market capital of $ 70.38 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Brainsway Ltd. will be hosting a conference call at 8:30 AM eastern time on 18th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-3982 Toll Free or 201-493-6780 Toll Number, with passcode : 13711444 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.brainsway.com
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimers disease, bipolar disorders, chronic pains, depressive disorders, Parkinsons diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
